Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity

Author:

Zheng Boyang1,Nevskaya Tatiana2,Baxter Carl A3,Ramey Dena R4,Pope Janet E25ORCID,Baron Murray16,Pope Janet E,Baron Murray,Hudson Marie,Gyger Geneviève,Larché Maggie J,Khalidi Nader A,Masetto Ariel,Sutton Evelyn,Robinson David,Rodriguez-Reyna Tatiana S,Smith Doug,Thorne Carter,Fortin Paul R,Fritzler Marvin J,Pope Janet E,Baron Murray,Hudson Marie,Gyger Geneviève,Larché Maggie J,Khalidi Nader A,Masetto Ariel,Sutton Evelyn,Robinson David,Rodriguez-Reyna Tatiana S,Smith Doug,Thorne Carter,Fortin Paul R,Fritzler Marvin J,

Affiliation:

1. Division of Rheumatology, McGill University, Montreal, QC, Canada

2. St Joseph Health Care, London, ON, Canada

3. MSD Ltd, Hoddesdon, UK

4. Merck & Co., Inc., Kenilworth, NJ, USA

5. Division of Rheumatology, Western University, London, ON, Canada

6. Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada

Abstract

Abstract Objective To determine whether skin score changes are associated with changes in overall disease severity, function and quality of life in early dcSSc patients. Methods A total of 154 and 128 dcSSc patients from the Canadian Scleroderma Research Group database with 1 and 2 year follow-up and a disease duration ⩽5 years without end-stage organ damage and/or significant comorbidity at the initial visit were included. Skin was assessed using the modified Rodnan skin score (mRSS) and disease severity by the summed Medsger disease severity score (DSS) (without skin domain), physician and patient global assessments, function [HAQ disability index (HAQ-DI)] and quality of life [36-item Short Form Health Survey (SF-36) physical component summary (PCS)]. Analyses were repeated in patients with a disease duration ⩽3 years. Results At 2 years, 64 (50%) patients had improved skin (mRSS decrease of ⩾5 points and/or ⩾25%). Skin improvers had improved summed DSS (P = 0.002); better physician global assessments of disease activity, severity and damage (all P ⩽ 0.003); better HAQ-DI (P = 0.001) and SF-36 PCS (P = 0.005). Changes in the mRSS were positively correlated with changes in summed DSS (P = 0.006) and other disease outcomes. In the 26 (20.3%) patients with worsened skin (mRSS increase of ⩾5 points and/or ⩾25%), the summed DSS and physician global assessments were worse (P = 0.01 and P ⩽ 0.009, respectively). In the subgroup with a disease duration ⩽3 years, similar associations were found. Conclusion At 1 and 2 years, overall disease improvement parallels skin improvement in early dcSSc. This is important for prognosis and reflects the value of mRSS as an outcome measure in trials with these patients.

Funder

Merck Sharp & Dohme Corp.

Merck & Co.

Inc.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3